PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30179004-0	2018	HLA-A*33:03-Restricted Activation of Ticlopidine-Specific T-Cells from Human Donors.	Ticlopidine	37-48	major histocompatibility complex, class I, A	Homo sapiens	0-5	
30179004-1	2018	The HLA class I allele HLA-A*33:03 is a risk factor for ticlopidine-induced liver injury.	Ticlopidine	56-67	major histocompatibility complex, class I, A	Homo sapiens	23-28	
30179004-2	2018	Herein, we show HLA class I-restricted ticlopidine-specific CD8+ T-cell activation in healthy donors expressing HLA-A*33:03.	Ticlopidine	39-50	major histocompatibility complex, class I, A	Homo sapiens	112-117	
28043905-16	2017	CONCLUSIONS: In a GWAS of persons of European descent with DILI, we associated HLA-A*33:01 with DILI due to terbinafine and possibly fenofibrate and ticlopidine.	Ticlopidine	149-160	major histocompatibility complex, class I, A	Homo sapiens	79-84	
17339877-2	2008	There was a significant correlation between ticlopidine-induced hepatotoxicity and five human leukocyte antigen (HLA) alleles: HLA-A*3303, HLA-B*4403, HLA-Cw*1403, HLA-DRB1*1302 and HLA-DQB1*0604 (corrected probability (P)-value (Pc)<0.01).	Ticlopidine	44-55	major histocompatibility complex, class I, A	Homo sapiens	127-132	
23635947-8	2013	Several HLA alleles also demonstrate drug-specific associations with DILI, such as HLA-A*33:03 for ticlopidine, HLA-B*57:01 for flucloxacillin and HLA-DQA1*02:01 for lapatinib.	Ticlopidine	99-110	major histocompatibility complex, class I, A	Homo sapiens	83-88	
17339877-3	2008	In particular HLA-A*3303 was present in 15 (68%) of the 22 patients with ticlopidine-induced hepatotoxicity and in 12 (14%) of the 85 ticlopidine-tolerant patients (odds ratio, 13.04; 95% confidence interval (CI), 4.40-38.59; the corrected P-value (Pc)=1.24 x 10(-5)).	Ticlopidine	73-84	major histocompatibility complex, class I, A	Homo sapiens	14-19	
17339877-3	2008	In particular HLA-A*3303 was present in 15 (68%) of the 22 patients with ticlopidine-induced hepatotoxicity and in 12 (14%) of the 85 ticlopidine-tolerant patients (odds ratio, 13.04; 95% confidence interval (CI), 4.40-38.59; the corrected P-value (Pc)=1.24 x 10(-5)).	Ticlopidine	134-145	major histocompatibility complex, class I, A	Homo sapiens	14-19	
17339877-4	2008	HLA-A*3303 was present in 12 (86%) of the 14 patients with ticlopidine-induced cholestatic hepatotoxicity (odds ratio, 36.50; 95% CI, 7.25-183.82, Pc=7.32 x 10(-7)).	Ticlopidine	59-70	major histocompatibility complex, class I, A	Homo sapiens	0-5	
17339877-5	2008	Ticlopidine-induced severe cholestatic hepatotoxicity occurred more frequently in subjects with HLA-A*3303 and its haplotype in Japanese patients.	Ticlopidine	0-11	major histocompatibility complex, class I, A	Homo sapiens	96-101